Krystal Biotech, Inc. KRYS
307.59 USD +2.56 (+0.84%)
Nov 4, 2026, 10:45 AM EST
301.80 Day range 314.75
192.52 52-week range 382.54
- YTD
- +24.76%
- 1 year
- +51.33%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 393.56 +28.0% upside
Now 307.59
- Target (low)
- 284.00
- Target (mean)
- 393.56
- Target (high)
- 474.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 12
- 2 months ago 12
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.65 | 1.49 – 3.04 | 1.70 | +56.1% | 126.54M | +29.4% | 10 |
| Next quarter | 1.94 | 1.99 – 4.06 | 1.70 | +14.1% | 135.28M | +16.3% | 4 |
| Current year | 8.05 | 7.29 – 10.48 | 6.84 | +17.7% | 498.10M | +28.0% | 7 |
| Next year | 9.00 | 6.47 – 11.97 | 8.05 | +11.8% | 639.37M | +28.4% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Nov 3, 2026 | TD Cowen | Maintained | Buy | Buy |
| Nov 3, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 21, 2026 | B of A Securities | Maintained | Buy | Buy |
| Aug 14, 2026 | RBC Capital | Initiated | — | Outperform |
| Aug 4, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 14, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jun 18, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jun 16, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 22, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 5, 2026 | Citigroup | Maintained | Buy | Buy |
| May 5, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 4, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 27, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Feb 25, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 18, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 18, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Feb 17, 2026 | Jefferies | Maintained | Buy | Buy |
| Feb 2, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 22, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jan 12, 2026 | Citigroup | Maintained | Buy | Buy |
| Jan 9, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jan 9, 2026 | Citigroup | Maintained | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 6, 2026 | Citigroup | Upgrade | Neutral | Buy |
| Nov 4, 2025 | Citigroup | Maintained | Neutral | Neutral |
| Nov 4, 2025 | Chardan Capital | Maintained | Buy | Buy |
